Related Experiment Videos

The importance of the eicosanoid pathway in lung cancer

Janessa J Laskin1, Alan B Sandler

  • 1Department of Medical Oncology and Hematology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 777 PRB, Nashville, TN 37215-6307, USA.

Lung Cancer (Amsterdam, Netherlands)
|July 18, 2003
PubMed

Insights

Non-steroidal anti-inflammatory agents (NSAIDs) show promise in fighting cancer. Research is exploring their effectiveness in treating non-small cell lung cancer (NSCLC), alone or with other therapies.

Area of Science:

  • Pharmacology
  • Oncology
  • Inflammation Research

Background:

  • Non-steroidal anti-inflammatory agents (NSAIDs) function by inhibiting eicosanoid production from arachadonic acid.
  • NSAIDs exhibit anti-cancer properties, particularly noted in colorectal cancer.
  • Pre-clinical studies suggest potential therapeutic applications for NSAIDs in non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the potential of NSAIDs as anti-cancer agents.
  • To evaluate the efficacy of eicosanoid inhibitors in the context of non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of pre-clinical models and ongoing clinical trials.
  • Analysis of NSAIDs' mechanism of action involving arachadonic acid metabolism.
  • Examination of combination therapies including NSAIDs with radiation and chemotherapy.

Main Results:

  • NSAIDs demonstrate anti-cancer effects, supported by colorectal cancer data.
  • Pre-clinical evidence indicates NSCLC treatment potential for NSAIDs.
  • Clinical trials are actively assessing NSAIDs' efficacy.

Conclusions:

  • NSAIDs represent a minimally toxic therapeutic option with demonstrated anti-cancer properties.
  • Further clinical investigation is warranted to establish NSAIDs' role in NSCLC treatment, potentially in combination therapies.

Related Concept Videos